Company / Return on Assets (ROA)
Apellis Pharmaceuticals, Inc. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
2.1%
FY2025
5-year range
-85.8% / 2.1%
FY2021-FY2025
Trend
+109.3%
vs FY2024
Sector context
#52 of 213
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s return on assets (roa) of 2.1% is higher than 76% of companies in the Health Care sector (FY2025). Return on Assets (ROA) has increased for 3 consecutive years, from -85.8% in FY2022 to 2.1% in FY2025.
Based on SEC 10-K filings.
2.1% in FY2025 with a 5-year CAGR of +38.0%. Top quartile in the Health Care sector.
Improved from -67.0% to 2.1% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +87.9pp
- 5-Year Change
- +38.0pp
- 10-Year Change
- -
Sector benchmark
+108.6% above sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s return on assets (roa) has grown for 3 consecutive years.
- In FY2025, return on assets (roa) increased 109.3% year-over-year.
- Currently 26.2pp above the Health Care sector average.
- Lowest return on assets (roa) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 2.1% | +109.3% |
| FY2024 | -22.4% | +66.6% |
| FY2023 | -67.0% | +21.9% |
| FY2022 | -85.8% | -1.4% |
| FY2021 | -84.6% | -135.8% |
| FY2020 | -35.9% | +54.1% |
| FY2019 | -78.3% | -25.0% |
| FY2018 | -62.6% | -123.6% |
| FY2017 | -28.0% | +71.7% |
| FY2016 | -98.9% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026